Dr. Reddy's Q1: The profit drop looks scary, but that's not the full story.

🔻 Revenue fell 6% YoY to ₹8,071 Cr, while Net Profit dropped 69% YoY to ₹444 Cr. But one important detail changes the picture. 📌 The company took a ₹240 Cr hit due to an issue related to the Semaglutide API, which impacted margins during the quarter. There were positives too. ✅ India business grew 17% YoY, Emerging Markets grew 31%, and the base business continued to see healthy growth despite lower Lenalidomide sales. The headline numbers look weak, but a one-time issue hurt the quarter. The underlying business continues to remain on a healthy footing.